Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations
作者： Ilenia Chatziandreou , Panagiota Tsioli , Stratigoula Sakellariou , Ioanna Mourkioti , Ioanna Giannopoulou
DOI: 10.1371/JOURNAL.PONE.0133859
关键词:
摘要: Background Selection of NSCLC patients for targeted therapy is currently based upon the presence sensitizing mutations in EGFR and EML4/ALK translocations. The heterogeneity molecular alterations lung cancer has led to ongoing discovery potential biomarkers targets order improve survival.
harvard.edu
paperity.org参考文章(78)
Masakuni Serizawa, Yasuhiro Koh, Hirotsugu Kenmotsu, Mitsuhiro Isaka, Haruyasu Murakami, Hiroaki Akamatsu, Keita Mori, Masato Abe, Isamu Hayashi, Tetsuhiko Taira, Tomohiro Maniwa, Toshiaki Takahashi, Masahiro Endo, Takashi Nakajima, Yasuhisa Ohde, Nobuyuki Yamamoto, Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, single-institute study Cancer. ,vol. 120, pp. 1471- 1481 ,(2014) , 10.1002/CNCR.28604
Rafael Rosell, Santiago Viteri, Miguel Angel Molina, José Miguel Sánchez-Torres, BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors Translational lung cancer research. ,vol. 2, pp. 244- 250 ,(2013) , 10.3978/J.ISSN.2218-6751.2013.04.01
Javier de Castro Carpeño, Cristóbal Belda-Iniesta, KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach Translational lung cancer research. ,vol. 2, pp. 142- 151 ,(2013) , 10.3978/J.ISSN.2218-6751.2013.02.07
Penelope Korkolopoulou, Georgia Levidou, Eleni-Andriana Trigka, Niki Prekete, Maria Karlou, Irene Thymara, Stratigoula Sakellariou, Paraskevi Fragkou, Dimitrios Isaiadis, Petros Pavlopoulos, Efstratios Patsouris, Angelica A. Saetta, A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma BJU International. ,vol. 110, pp. E1237- E1248 ,(2012) , 10.1111/J.1464-410X.2012.11569.X
Ying Wang, Shumin Wang, Shiguang Xu, Jiaqi Qu, Bo Liu, Clinicopathologic Features of Patients with Non-Small Cell Lung Cancer Harboring the EML4-ALK Fusion Gene: A Meta-Analysis PLOS ONE. ,vol. 9, ,(2014) , 10.1371/JOURNAL.PONE.0110617
Yuan Li, Yunjian Pan, Rui Wang, Yihua Sun, Haichuan Hu, Xuxia Shen, Yongming Lu, Lei Shen, Xiongzeng Zhu, Haiquan Chen, ALK-Rearranged Lung Cancer in Chinese: A Comprehensive Assessment of Clinicopathology, IHC, FISH and RT-PCR PLoS ONE. ,vol. 8, pp. e69016- ,(2013) , 10.1371/JOURNAL.PONE.0069016
Thanyanan Reungwetwattana, Saravut J. Weroha, Julian R. Molina, Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC) Clinical Lung Cancer. ,vol. 13, pp. 252- 266 ,(2012) , 10.1016/J.CLLC.2011.09.004
Filip Janku, Jennifer J. Wheler, Aung Naing, Gerald S. Falchook, David S. Hong, Vanda M. Stepanek, Siqing Fu, Sarina A. Piha-Paul, J. Jack Lee, Rajyalakshmi Luthra, Apostolia M. Tsimberidou, Razelle Kurzrock, PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials Cancer Research. ,vol. 73, pp. 276- 284 ,(2013) , 10.1158/0008-5472.CAN-12-1726
Takafumi Kubo, Hiromasa Yamamoto, William W. Lockwood, Ilse Valencia, Junichi Soh, Michael Peyton, Masaru Jida, Hiroki Otani, Tetsuya Fujii, Mamoru Ouchida, Nagio Takigawa, Katsuyuki Kiura, Kenji Shimizu, Hiroshi Date, John D. Minna, Marileila Varella-Garcia, Wan L. Lam, Adi F. Gazdar, Shinichi Toyooka, MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. International Journal of Cancer. ,vol. 124, pp. 1778- 1784 ,(2009) , 10.1002/IJC.24150
Tetsuya Mitsudomi, Yasushi Yatabe, Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Science. ,vol. 98, pp. 1817- 1824 ,(2007) , 10.1111/J.1349-7006.2007.00607.X